In this review, we aimed to study the potential of SAA to be a therapeutic target to combat hyper-inflammatory syndrome associated with COVID-19 based on the common feature of inflammation between arthritides, vasculitis, and COVID-19 hyperinflammation. The gene discussed is SAA1; the disease is COVID-19.